Atai Beckley N.V
General ticker "ATAI" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $889.5M (TTM average)
Atai Beckley N.V follows the US Stock Market performance with the rate: 18.4%.
Estimated limits based on current volatility of 8.3%: low 6.04$, high 7.13$
Factors to consider:
- Total employees count: 54 (-34.9%) as of 2024
- Top business risk factors: Need for additional capital, Dependence on key products, Regulatory and compliance, Cybersecurity threats, Investment company act risk
- Current price 15.3% above estimated high
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.64$, 6.26$]
- 2026-12-31 to 2027-12-31 estimated range: [1.95$, 4.88$]
Financial Metrics affecting the ATAI estimates:
- Positive: with PPE of -6.6 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Shareholder equity ratio, % of 71.45 > 64.23
- Negative: Industry operating cash flow per share per price (median), % of 0.76 <= 5.50
- Negative: 0.01 < Interest expense per share per price, % of 0.13
- Positive: Inventory ratio change, % of -27.15 <= -0.75
Short-term ATAI quotes
Long-term ATAI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.31MM | $0.31MM | $4.09MM |
| Operating Expenses | $125.78MM | $103.00MM | $103.85MM |
| Operating Income | $-125.47MM | $-102.69MM | $-99.76MM |
| Non-Operating Income | $82.59MM | $-48.24MM | $-560.09MM |
| Interest Expense | $2.66MM | $3.12MM | $1.16MM |
| R&D Expense | $61.88MM | $54.98MM | $53.06MM |
| Income(Loss) | $-42.88MM | $-150.93MM | $-659.85MM |
| Taxes | $1.02MM | $-0.88MM | $0.30MM |
| Net Income(Loss)* | $-40.22MM | $-149.27MM | $-660.05MM |
| Stockholders Equity | $242.96MM | $116.30MM | $221.87MM |
| Assets | $293.48MM | $159.39MM | $310.54MM |
| Operating Cash Flow | $-84.12MM | $-82.44MM | $-102.67MM |
| Capital expenditure | $0.59MM | $0.10MM | $0.90MM |
| Investing Cash Flow | $-53.30MM | $59.17MM | $-109.13MM |
| Financing Cash Flow | $-8.36MM | $5.37MM | $269.48MM |
| Earnings Per Share** | $-0.25 | $-0.93 | $-2.91 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.